Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial

BACKGROUND: Dose modifications following adverse events (AEs) are an important part of the management of patients with pancreatic cancer treated with chemotherapy. While dose modifications are utilized to ensure patient safety, the subsequent influence of dose adjustments on treatment exposure and e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Scheithauer, Werner, Ramanathan, Ramesh K., Moore, Malcolm, Macarulla, Teresa, Goldstein, David, Hammel, Pascal, Kunzmann, Volker, Liu, Helen, McGovern, Desmond, Romano, Alfredo, Von Hoff, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4880765/
https://ncbi.nlm.nih.gov/pubmed/27284481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.01.03
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados